Age-Specific Reference Intervals for Plasma Free Thyroxine and Thyrotropin in Term Neonates During the First Two

Jolanda C Naafs1, Charlotte A Heinen1, Nitash Zwaveling-Soonawala1

  • 1Department of Pediatric Endocrinology, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.

Insights

New reference intervals for neonatal screening help diagnose congenital hypothyroidism (CH). Establishing age-specific ranges for free thyroxine (fT4) and thyrotropin (TSH) improves detection of CH, a preventable cause of developmental delay.

Area of Science:

  • Neonatal endocrinology
  • Clinical diagnostics
  • Pediatric screening

Background:

  • Congenital hypothyroidism (CH) is a key preventable cause of mental retardation.
  • Accurate diagnosis of CH, particularly central CH (CH-C), relies on plasma free thyroxine (fT4) and thyrotropin (TSH) levels.
  • Current neonatal reference intervals (RIs) for fT4 and TSH are insufficient, hindering effective CH diagnosis.

Purpose of the Study:

  • To establish age-specific neonatal reference intervals (RIs) for plasma fT4 and TSH.
  • To provide a reliable lower limit for fT4 RIs to aid in diagnosing CH-C.
  • To support improved diagnostic accuracy in neonatal screening programs for CH.

Main Methods:

  • Blood samples were collected from 146 healthy neonates at two time points: days 3-7 and days 13-15.
  • Plasma fT4 and TSH concentrations were measured using an immunoassay (Cobas; Roche Diagnostics).
  • Ninety-five percent RIs were calculated using standard statistical methods based on data distribution.

Main Results:

  • Established 95% RIs for fT4: 20.5-37.1 pmol/L (days 3-7) and 15.3-26.5 pmol/L (days 13-15).
  • Established 95% RIs for TSH: 1.0-8.4 mU/L (days 3-7) and 1.4-8.6 mU/L (days 13-15).
  • The lower limit of the fT4 RI was found to be significantly higher than adult RIs.

Conclusions:

  • The established neonatal RIs for fT4 and TSH are crucial for accurate CH diagnosis.
  • The lower fT4 limit of 20.5 pmol/L (3-7 days) and 15.3 pmol/L (13-15 days) is vital for identifying CH-C.
  • Recommendations include using assays with established neonatal RIs and considering the neonate's age in days for CH screening.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
202
Synthesis and Regulation of Thyroid Hormones01:20

Synthesis and Regulation of Thyroid Hormones

Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
6.8K
Functions of Thyroid Hormones01:18

Functions of Thyroid Hormones

The thyroid hormone (TH) plays a pivotal role in the intricate orchestration of physiological processes, exerting profound effects on development, metabolism, and homeostasis throughout different life stages.
TH is indispensable for the normal development and maturation of the skeletal, muscular, and nervous systems during fetal and childhood growth. It facilitates bone mineral turnover and regulates protein synthesis in developing tissues, contributing significantly to overall growth and...
4.7K
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
146
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
189
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
159